Seaport Therapeutics reports positive Phase 1 data for GlyphAgo™ in generalized anxiety disorder
Seaport Therapeutics (NASDAQ:SPTX) announced today positive data from the multiple-ascending dose (MAD) portion of its Phase 1 proof-of-concept clinical trial for GlyphAgo™ (SPT-320).










